Vaxcyte SEC Filings
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
71.38+6.36 (+9.79%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Vaxcyte filing overview
This page lists 3 recent SEC filings by Vaxcyte (PCVX), including 2 4, 1 8-K. The latest current report (8-K), used to disclose material events such as earnings releases and executive changes, was filed on Oct 9, 2026. Form 10-K is the audited annual report, 10-Q the quarterly report, 8-K covers material events, and Form 4 reports insider transactions. All documents link directly to SEC EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
PCVX SEC filings
| Filed | Form | Description | Document |
|---|---|---|---|
| Oct 9, 2026 | 8-K | Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement; Other Events | View on EDGAR |
| Oct 7, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |
| Oct 7, 2026 | 4 | Statement of changes in beneficial ownership | View on EDGAR |